| Literature DB >> 31373325 |
Kevin M Carroll1, Caleb D Bazyler2, Jake R Bernards2, Christopher B Taber3, Charles A Stuart4, Brad H DeWeese2, Kimitake Sato2, Michael H Stone2.
Abstract
The purpose of the study was to compare the physiological responses of skeletal muscle to a resistance training (RT) program using repetition maximum (RM) or relative intensity (RISR). Fifteen well-trained males underwent RT 3 d·wk-1 for 10 weeks in either an RM group (n = 8) or RISR group (n = 7). The RM group achieved a relative maximum each day, while the RISR group trained based on percentages. The RM group exercised until muscular failure on each exercise, while the RISR group did not reach muscular failure throughout the intervention. Percutaneous needle biopsies of the vastus lateralis were obtained pre-post the training intervention, along with ultrasonography measures. Dependent variables were: Fiber type-specific cross-sectional area (CSA); anatomical CSA (ACSA); muscle thickness (MT); mammalian target of rapamycin (mTOR); adenosine monophosphate protein kinase (AMPK); and myosin heavy chains (MHC) specific for type I (MHC1), type IIA (MHC2A), and type IIX (MHC2X). Mixed-design analysis of variance and effect size using Hedge's g were used to assess within- and between-group alterations. RISR statistically increased type I CSA (p = 0.018, g = 0.56), type II CSA (p = 0.012, g = 0.81), ACSA (p = 0.002, g = 0.53), and MT (p < 0.001, g = 1.47). RISR also yielded a significant mTOR reduction (p = 0.031, g = -1.40). Conversely, RM statistically increased only MT (p = 0.003, g = 0.80). Between-group effect sizes supported RISR for type I CSA (g = 0.48), type II CSA (g = 0.50), ACSA (g = 1.03), MT (g = 0.72), MHC2X (g = 0.31), MHC2A (g = 0.87), and MHC1 (g = 0.59); with all other effects being of trivial magnitude (g < 0.20). Our results demonstrated greater adaptations in fiber size, whole-muscle size, and several key contractile proteins when using RISR compared to RM loading paradigms.Entities:
Keywords: athlete; hypertrophy; muscle fiber; muscle force; strength
Year: 2019 PMID: 31373325 PMCID: PMC6680702 DOI: 10.3390/sports7070169
Source DB: PubMed Journal: Sports (Basel) ISSN: 2075-4663
Resistance Training Programs.
| RISR | RM Zone | ||||
|---|---|---|---|---|---|
| Training Block | Week | (Sets) × (Reps) | Day 1 and 2 | Day 3 | |
| (A) VJ and IMTP Testing | |||||
| Strength-Endurance | 1 | 3 × 10 | 80.0% | 70.0% | 3 × 8−12 |
| 2 | 3 × 10 | 85.0% | 75.0% | 3 × 8−12 | |
| 3 | 3 × 10 | 90.0% | 80.0% | 3 × 8−12 | |
| (B) VJ and IMTP Testing | |||||
| Max-Strength * | 4 | 3 × 5 | 85.0% | 70.0% | 3 × 4−6 |
| 5 | 3 × 5 | 87.5% | 72.5% | 3 × 4−6 | |
| 6 | 3 × 5 | 92.5% | 75.0% | 3 × 4−6 | |
| 7 | 3 × 5 | 80.0% | 65.0% | 3 × 4−6 | |
| (C) VJ and IMTP Testing | |||||
| Overreach | 8 | 5 × 5 | 85.0% | 75.0% | 5 × 4−6 |
| (D) VJ and IMTP Testing | |||||
| Speed-Strength | 9 | 3 × 3 | 87.5% | 67.5% | 3 × 2−4 |
| 10 | 3 × 2 | 85.0% | 65.0% | 3 × 1−3 | |
| (E) VJ and IMTP testing | |||||
* Symbolizes down set at 60% of working weight (RISR only), RISR = relative intensity based on sets and repetitions, RM = repetition maximum, VJ = vertical jump, IMTP = isometric mid-thigh pull.
Training Exercises for all subjects.
| Training Block | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| Strength-Endurance | Back Squat, Overhead Press, Bench Press, DB Tricep Ext. | CG MTP, CG SLDL, BB Bent-Row, DB Bent Lateral Raise | Back Squat, Overhead Press, Bench Press, DB Tricep Ext. |
| Max-Strength | Back Squat, Push Press, Incline Bench Press, Wtd. Dips | CG MTP, Clean Pull, SG SLDL, Pull-Ups | Back Squat, Push Press, Incline Bench Press, Wtd. Dips |
| Overreach | Back Squat, Push Press, DB Step Up, Bench Press | CG CM Shrug, Clean Pull, CG SLDL, SA DB Bent-Row | Back Squat, Push Press, DB Step Up, Bench Press |
| Speed-Strength | Back Squat + Rocket Jump, Push Press, Bench Press + Med Ball Chest Pass | CG MTP, CG CM Shrug, Vertical Med Ball Toss | Back Squat + Rocket Jump, Push Press, Bench Press + Med Ball Chest Pass |
DB = dumbbell, CG = clean grip, MTP = mid-thigh pull, BB = barbell, Ext = extension, Wtd. = weighted, SG = snatch grip, SLDL = stiff-legged deadlift, SA = single arm, CM = counter-movement.
Figure 1Example of histochemical stains for myosin heavy-chain (MHC) isoforms: MHC2X (type IIX; green), MHC2A (type IIA; blue), and MHC1 (type I; red). Scale = 100 µm.
Figure 2Immunoblots for mammalian target of rapamycin (mTOR), adenosine monophosphate kinase (AMPK), and the myosin heavy-chain (MHC) isoforms: MHC2X, MHC2A, and MHC1. Immunoblots were performed with a marker in the first lane, followed by the first subject’s pre-value and their post-value. This was repeated for all subjects and proteins.
Figure 3Changes in (A) type I and (B) type II cross-sectional area (CSA) pre- to post-intervention. * denotes significance for relative intensity group, p ≤ 0.05.
Figure 4Changes in (A) anatomical cross-sectional area (ACSA) and (B) muscle thickness measured by ultrasonography pre- to post-intervention. * denotes significance for relative intensity group, p ≤ 0.05. † denotes significance for RM group, p ≤ 0.05.
Muscle size effect size using Hedge’s g and 90% confidence intervals for within-group and between-group effects.
| Relative Intensity Effects | Repetition Maximum Effects | Between-Group Effects | |||||
|---|---|---|---|---|---|---|---|
| Variable | pre ± SD | post ± SD | pre ± SD | post ± SD | |||
| Type I CSA (µm2) | 0.56 (0.22–0.89) | 3277 ± 692 | 3720 ± 793 | 0.26 (−0.02–0.54) | 3470 ± 789 | 3713 ± 974 | 0.48 (−0.35–1.31) |
| Type II CSA (µm2) | 0.81 (0.37–1.26) | 4079 ± 1195 | 5839 ± 1399 | 0.49 (−0.05–1.02) | 4883 ± 1137 | 5493 ± 1241 | 0.50 (−0.33–1.33) |
| ACSA (cm2) | 0.53 (0.33–0.73) | 39.10 ± 6.25 | 42.53 ± 5.76 | 0.14 (0.00–0.28) | 40.77 ± 9.22 | 42.09 ± 8.75 | 1.03 (0.20–1.86) |
| MT (cm2) | 1.47 (0.99–1.95) | 2.12 ± 0.33 | 3.62 ± 0.32 | 0.80 (0.46–1.14) | 2.48 ± 0.38 | 2.83 ± 0.43 | 0.72 (−0.11–1.55) |
g = Hedge’s g effect size, CI = 90% confidence interval, SD = standard deviation, CSA = cross-sectional area, ACSA = anatomical cross-sectional area, MT = muscle thickness.
Figure 5Fold-change results from immunoblotting for mammalian target of rapamycin (mTOR), adenosine monophosphate kinase (AMPK), and the myosin heavy-chain (MHC) isoforms: MHC2X, MHC2A, and MHC1. * denotes significance for relative intensity group, p ≤ 0.05.
Western blot effect size using Hedge’s g and 90% confidence intervals for within-group and between-group effects.
| Relative Intensity Effects | Repetition Maximum Effects | Between-Group Effects | |||
|---|---|---|---|---|---|
| Fold Change ± SD | Fold Change ± SD | ||||
| mTOR (AU) | −1.40 (−2.38–−0.43) | −0.22 ± 0.21 | −0.97 (−1.86–−0.07) | −0.23 ± 0.33 | 0.02 (−0.80–0.85) |
| AMPK (AU) | −0.19 (−1.16–0.78) | −0.10 ± 0.70 | −0.01 (−0.90–0.88) | −0.01 ± 0.81 | −0.11 (−0.94–0.72) |
| MHC2X (AU) | 0.93 (−0.04–1.90) | 1.22 ± 1.74 | 0.44 (−0.46–1.33) | 0.61 ± 1.85 | 0.31 (−0.52–1.14) |
| MHC2A (AU) | 0.96 (−0.01–1.93) | 1.70 ± 2.34 | 0.24 (−0.66–1.14) | 0.13 ± 0.70 | 0.87 (0.02–1.73) |
| MHC1 (AU) | 0.78 (−0.19–1.75) | 0.50 ± 0.85 | 0.37 (−0.52–1.27) | 0.10 ± 0.36 | 0.59 (−0.27–1.44) |
g = Hedge’s g effect size, mTOR = mammalian target of rapamycin, AMPK = adenosine monophosphate protein kinase, MHC = myosin heavy chain.